专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

1. 发明申请

WO2005092377A9 CYTOTOXICITY MEDIATION OF CELLS EVIDENCING SURFACE EXPRESSION OF CD63 审中-公开
标题翻译：细胞表达CD63细胞表达表达的细胞毒性介质
公开(公告)号：WO2005092377A9
公开(公告)日：2007-03-22
申请号：PCT/CA2005000443
申请日：2005-03-23
申请人： ARIUS RES INC
发明人： YOUNG DAVID S F , HAHN SUSAN E , FINDLAY HELEN P , DA CRUZ LUIS A G
IPC分类号： A61K39/395 , A61K47/48 , A61K51/10 , A61P35/00 , C07K16/00 , C07K16/28 , C07K16/30 , G01N33/574
CPC分类号： A61K51/1045 , A61K47/6851 , A61K51/1051 , A61K51/1096 , A61K2039/505 , C07K16/00 , C07K16/2896 , C07K16/30 , C07K16/3015 , C07K16/3023 , C07K16/3046 , C07K16/3069 , C07K16/3076 , G01N33/57484 , G01N33/57492
摘要： The use of a cancerous disease modifying antibody (CDMAB) 7BD-33-11A, for treating a tumor in humans and methods of isolating and identifying cancerous cells which express a CD63 antygenic moiety. The monoclonal antibody 7BD-33-11A (ATCC accesssion number PTA-4890), which binds a CD63 antigenic moiety, is cytotoxic to cancer cells which express the antigenic moiety. The monoclonal antibody 7BD-33-11A is useful for delaying the disease progression of a human tumor.
摘要翻译：使用用于治疗人类肿瘤的癌性疾病修饰抗体（CDMAB）7BD-33-11A以及分离和鉴定表达CD63致病性部分的癌细胞的方法。结合CD63抗原部分的单克隆抗体7BD-33-11A（ATCC存取号PTA-4890）对表达抗原部分的癌细胞具有细胞毒性。单克隆抗体7BD-33-11A可用于延缓人类肿瘤的疾病进展。

2. 发明申请

WO2007095746A9 CANCEROUS DISEASE MODIFYING ANTIBODIES 审中-公开
公开(公告)号：WO2007095746A9
公开(公告)日：2008-10-23
申请号：PCT/CA2007000279
申请日：2007-02-22
申请人： ARIUS RES INC
发明人： YOUNG DAVID S F , FINDLAY HELEN P , HAHN SUSAN E , SAYEGH DAAD
IPC分类号： C12N5/16 , A61K39/00 , A61K39/395 , A61K47/48 , A61K51/10 , A61P35/00 , C07K16/18 , C07K16/30 , C12P21/08 , G01N33/574 , G01N33/577
CPC分类号： C07K16/30 , A61K47/6851 , A61K51/1045 , A61K2039/505
摘要： The present invention relates to a method for producing cancerous disease modifying antibodies using a novel paradigm of screening. By segregating lhe anti- cancer antibodies using cancer cell cytotoxicity as an end point, the process makes possible the production of anti-cancer antibodies for therapeutic and diagnostic purposes. The antibodies can be used in aid of staging and diagnosis of a cancer, and can be used to treat primary tumors and tumor metastases. The anti-cancer antibodies can be conjugated to toxins, enzymes, radioactive compounds, cytokines, interferons, target or reporter moieties and hematogenous cells.
摘要翻译：本发明涉及使用新颖的筛选范例来生产癌性疾病修饰抗体的方法。通过使用癌细胞细胞毒性将抗癌抗体分离为终点，该方法使得可能产生用于治疗和诊断目的的抗癌抗体。抗体可用于帮助分期和诊断癌症，并可用于治疗原发性肿瘤和肿瘤转移。抗癌抗体可以与毒素，酶，放射性化合物，细胞因子，干扰素，靶或报告物部分和血细胞结合。

3. 发明申请

WO2007095749A8 CYTOTOXICITY MEDIATION OF CELLS EVIDENCING SURFACE EXPRESSION OF TROP-2 审中-公开
标题翻译：细胞凋亡诱导TROP-2的表达表达
公开(公告)号：WO2007095749A8
公开(公告)日：2009-01-29
申请号：PCT/CA2007000283
申请日：2007-02-23
申请人： ARIUS RES INC
发明人： YOUNG DAVID S F , FINDLAY HELEN P , HAHN SUSAN E , DACRUZ LUIS A G , FERRY ALISON L
IPC分类号： C12N5/16 , A61K39/00 , A61K39/395 , A61K47/48 , A61K51/10 , A61P35/00 , C07K16/18 , C07K16/30 , C12P21/08 , G01N33/574 , G01N33/577
CPC分类号： C07K16/30 , A61K47/6851 , A61K51/1045 , A61K2039/505 , C07K2317/24 , C07K2317/56 , C07K2317/565 , G01N33/57484
摘要： The present invention relates to a method for producing cancerous disease modifying antibodies using a novel paradigm of screening. By segregating the anti-cancer antibodies using cancer cell cytotoxicity as an end point, the process makes possible the production of anti-cancer antibodies for therapeutic and diagnostic purposes. The antibodies can be used in aid of staging and diagnosis of a cancer, and can be used to treat primary tumors and tumor metastases. The anti-cancer antibodies can be conjugated to toxins, enzymes, radioactive compounds, cytokines, interferons, target or reporter moieties and hematogenous cells.
摘要翻译：本发明涉及使用新颖的筛选范例制备癌性疾病修饰抗体的方法。通过使用癌细胞细胞毒性分离抗癌抗体作为终点，该方法使得可能产生用于治疗和诊断目的的抗癌抗体。抗体可用于帮助分期和诊断癌症，并可用于治疗原发性肿瘤和肿瘤转移。抗癌抗体可以与毒素，酶，放射性化合物，细胞因子，干扰素，靶或报告物部分和血细胞结合。

4. 发明申请

WO03074568A9 INDIVIDUALIZED ANTI-CANCER ANTIBODIES 审中-公开
标题翻译：个体化的抗癌抗体
公开(公告)号：WO03074568A9
公开(公告)日：2003-12-11
申请号：PCT/IB0002050
申请日：2000-11-08
申请人： ARIUS RES INC
发明人： YOUNG DAVID S F , TAKAHASHI MIYOKO
IPC分类号： A61K38/00 , A61K35/12 , A61K38/43 , A61K39/39 , A61K39/395 , A61K47/48 , A61K51/00 , A61K51/10 , A61P35/00 , C07K16/30
CPC分类号： C07K16/00 , A61K47/68 , A61K51/10 , A61K2039/505 , C07K16/3007 , C07K16/3015 , C07K16/3053
摘要： The present invention relates to a method for producing patient specific anti-cancer antibodies using a novel paradigm of screening. By segregating the anti-cancer antibodies using cancer cell sytotoxicity as an end point, the process makes possible the production of anti-cancer antibodies customized for the individual patient that can be used for therapeutic and diagnostic purposes. The invention further relates to the process by which the antibodies are made and to their methods of use. The antibodies can be made specifically for one tumor derived from a particular patient and are selected on the basis of their cancer cell cytotoxicity and simultaneous lack of toxicity for non-cancerous cells. The antibodies can be used in aid of staging and diagnosis of a cancer, and can be used to treat tumor metastases. The anti-cancer antibodies can be conjugated to red blood cells obtained from that patient and re-infused for treatment of metastases based upon the recognition that metastatic cancers are usually well vascularized and the delivery of anti-cancer antibodies by red blood cells can have the effect of concentrating the antibodies at the site of the tumor.
摘要翻译：本发明涉及使用新型筛选范例产生患者特异性抗癌抗体的方法。通过使用癌细胞的细胞毒性作为终点分离抗癌抗体，该过程使得为个体患者定制的可用于治疗和诊断目的的抗癌抗体的生产成为可能。本发明进一步涉及制备抗体的方法及其使用方法。抗体可以针对来自特定患者的一种肿瘤特异性地制备，并基于其癌细胞的细胞毒性和对非癌细胞同时缺乏毒性进行选择。这些抗体可用于癌症的分期和诊断，并可用于治疗肿瘤转移。基于认识到转移性癌症通常良好血管化并且红血细胞递送抗癌抗体可以使抗癌抗体与从患者获得的红细胞缀合并且再注入用于治疗转移的抗癌抗体可以具有在肿瘤部位浓缩抗体的效果。

5. 发明申请

WO2007095729A8 CYTOTOXICITY MEDIATION OF CELLS EVIDENCING SURFACE EXPRESSION OF CD63 审中-公开
标题翻译：细胞的细胞毒性介导CD63表达表达
公开(公告)号：WO2007095729A8
公开(公告)日：2009-07-16
申请号：PCT/CA2007000254
申请日：2007-02-22
申请人： ARIUS RES INC , YOUNG DAVID S F , FINDLAY HELEN P , HAHN SUSAN E , DACRUZ LUIS A G , SAYEGH DAAD , ROGERS KRISTIAN , KUMAR SHANKAR , HINTON PAUL
发明人： YOUNG DAVID S F , FINDLAY HELEN P , HAHN SUSAN E , DACRUZ LUIS A G , SAYEGH DAAD , ROGERS KRISTIAN , KUMAR SHANKAR , HINTON PAUL
IPC分类号： C12N5/12 , A61K39/395 , A61K47/48 , A61P35/00 , C07K16/30 , G01N33/567 , G01N33/574
CPC分类号： G01N33/57492 , A61K47/6849 , A61K47/6851 , A61K51/1027 , A61K51/1045 , A61K2039/505 , C07K16/2896 , C07K16/30 , C07K2317/24 , C07K2317/732 , C07K2317/92 , G01N33/56966 , G01N33/5743 , G01N2333/70596
摘要： This invention relates to the diagnosis and treatment of cancerous diseases, particularly to the mediation of cytotoxicity of tumor cells; and most particularly to the use of cancerous disease modifying antibodies (CDlVIAB), optionally in combination with one or more chemotherapeutic agents, as a means for initiating the cytotoxic response. The invention further relates to binding assays which utilize the CDMAB of the instant invention.
摘要翻译：本发明涉及癌症的诊断和治疗，特别涉及肿瘤细胞的细胞毒性的介导; 并且最特别地涉及使用任选与一种或多种化学治疗剂组合的癌性疾病修饰抗体（CD1VIAB）作为起始细胞毒性应答的手段。本发明还涉及利用本发明的CDMAB的结合测定法。

6. 发明申请

WO2007014455A9 CANCEROUS DISEASE MODIFYING ANTIBODIES 审中-公开
标题翻译：癌症疾病修改抗体
公开(公告)号：WO2007014455A9
公开(公告)日：2007-03-22
申请号：PCT/CA2006001246
申请日：2006-08-01
申请人： ARIUS RES INC
发明人： YOUNG DAVID S F , HAHN SUSAN E , CECHETTO LISA M
IPC分类号： C12P21/08 , A61K39/395 , A61P35/00 , C07K16/18 , C07K16/30 , C07K16/46 , C12N5/16 , G01N33/567 , G01N33/574
CPC分类号： C07K16/30 , A61K2039/505 , C07K2317/73 , G01N33/567 , G01N33/574
摘要： The present invention relates to a method for producing patient cancerous disease modifying antibodies using a novel paradigm of screening. By segregating the anti-cancer antibodies using cancer cell cytotoxicity as an end point, the process makes possible the production of anti-cancer antibodies for therapeutic and diagnostic purposes. The antibodies can be used in aid of staging and diagnosis of a cancer, and can be used to treat primary tumors and tumor metastases. The anti-cancer antibodies can be conjugated to toxins, enzymes, radioactive compounds, and hematogenous cells.
摘要翻译：本发明涉及使用新型筛选范例产生患者癌性疾病修饰抗体的方法。通过使用癌细胞细胞毒性作为终点分离抗癌抗体，该过程使得用于治疗和诊断目的产生抗癌抗体成为可能。这些抗体可用于癌症的分期和诊断，并可用于治疗原发性肿瘤和肿瘤转移。抗癌抗体可以与毒素，酶，放射性化合物和血源性细胞缀合。

7. 发明申请

WO2004065422A3 CANCEROUS DISEASE MODIFYING ANTIBODIES 审中-公开
公开(公告)号：WO2004065422A3
公开(公告)日：2004-11-11
申请号：PCT/CA2004000059
申请日：2004-01-21
申请人： ARIUS RES INC
发明人： YOUNG DAVID S F , HAHN SUSAN E , FINDLAY HELEN P
IPC分类号： A61K51/10 , A61P35/00 , C07K16/00 , C07K16/30 , C12N5/18 , G01N33/574 , A61K39/395
CPC分类号： C07K16/30 , A61K51/1045 , A61K51/1051 , A61K51/1096 , A61K2039/505 , C07K16/00 , C07K16/3015 , C07K16/3023 , C07K16/3046 , C07K16/3069 , G01N33/57484
摘要： The present invention relates to a method for producing patient cancerous disease modifying antibodies using a novel paradigm of screening. By segregating the anti-cancer antibodies using cancer cell cytotoxicity as an end point, the process makes possible the production of anti-cancer antibodies for therapeutic and diagnostic purposes. The antibodies can be used in aid of staging and diagnosis of a cancer, and can be used to treat primary tumors and tumor metastases. The anti-cancer antibodies can be conjugated to toxins, enzymes, radioactive compounds, and hematogenous cells.

8. 发明申请

WO2008058380A8 CANCEROUS DISEASE MODIFYING ANTIBODIES 审中-公开
公开(公告)号：WO2008058380A8
公开(公告)日：2009-07-02
申请号：PCT/CA2007002028
申请日：2007-11-13
申请人： ARIUS RES INC , YOUNG DAVID S F , FINDLAY HELEN P , HAHN SUSAN E , CECHETTO LISA M
发明人： YOUNG DAVID S F , FINDLAY HELEN P , HAHN SUSAN E , CECHETTO LISA M
IPC分类号： C12N5/18 , A61K39/395 , A61K47/48 , A61K51/10 , A61P35/00 , A61P37/04 , C07K16/18 , C07K16/30 , C07K16/46 , C12P21/08 , G01N33/574 , G01N33/577
CPC分类号： G01N33/574 , A61K47/6851 , A61K51/1045 , A61K2039/505 , C07K16/30 , C07K16/3046 , C07K2317/21
摘要： The present invention relates to a method for producing cancerous disease modifying antibodies using a novel paradigm of screening. By segregating the anti-cancer antibodies using cancer cell cytotoxicity as an end point, the process makes possible the production of anti-cancer antibodies for therapeutic and diagnostic purposes. The antibodies can be used in aid of staging and diagnosis of a cancer, and can be used to treat primary tumors and tumor metastases. The anti-cancer antibodies can be conjugated to toxins, enzymes, radioactive compounds, and hematogenous cells.
摘要翻译：本发明涉及使用新颖的筛选范例制备癌性疾病修饰抗体的方法。通过使用癌细胞细胞毒性分离抗癌抗体作为终点，该方法使得可能产生用于治疗和诊断目的的抗癌抗体。抗体可用于帮助分期和诊断癌症，并可用于治疗原发性肿瘤和肿瘤转移。抗癌抗体可以与毒素，酶，放射性化合物和血细胞结合。

9. 发明申请

WO2005012361A3 ANTIBODIES RAISED AGAINST COLON CARCINOMAS 审中-公开
标题翻译：抗体结合抗体
公开(公告)号：WO2005012361A3
公开(公告)日：2005-05-19
申请号：PCT/CA2004000988
申请日：2004-07-23
申请人： ARIUS RES INC
发明人： YOUNG DAVID S F , HAHN SUSAN E , FINDLAY HELEN P
IPC分类号： A61P35/00 , C07K16/30 , G01N33/569 , G01N33/574 , A61K39/395
CPC分类号： G01N33/56966 , A61K2039/505 , C07K16/3015 , C07K16/303 , C07K16/3046 , C07K16/3069 , G01N33/57415 , G01N33/57419 , G01N33/57423 , G01N33/57434 , G01N33/57438 , G01N33/57449
摘要： The present invention relates to a method for producing patient cancerous disease modifying antibodies using a novel paradigm of screening. By segregating the anti-cancer antibodies using cancer cell cytotoxicity as an end point, the process makes possible the production of anti-cancer antibodies for therapeutic and diagnostic purposes. The antibodies can be used in aid of staging and diagnosis of a cancer, and can be used to treat primary tumors and tumor metastases. The anti-cancer antibodies can be conjugated to toxins, enzymes, radioactive compounds, and hematogenous cells.
摘要翻译：本发明涉及使用新的筛选范例来生产患者癌症疾病修饰抗体的方法。通过使用癌细胞细胞毒性分离抗癌抗体作为终点，该方法使得可能产生用于治疗和诊断目的的抗癌抗体。抗体可用于帮助分期和诊断癌症，并可用于治疗原发性肿瘤和肿瘤转移。抗癌抗体可以与毒素，酶，放射性化合物和血细胞结合。

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式